Be first to read the latest tech news, Industry Leader's Insights, and CIO interviews of medium and large enterprises exclusively from MD Tech Review
Md Tech Review
“High pain scores following surgical procedures are common and are associated with poor patient outcomes;but on the other hand we know that excessive use of opioids administered during the surgery itself to prevent postoperative pain can cause other complications,” explains Prof. Dahan of Leiden University Medical Center’s Department of Anesthesiology, who led the study.
NOL monitoring provides a reliable index to objectively detect and quantify noxious stimuli during anaesthesia, when patients can’t communicate, guiding the clinical team in tailored opioid dosing for each patient. Earlier studies have shown that the NOL index outperforms other indexes for monitoring of pain response to surgical stimuliand that NOL-guided analgesia resulted in reduced intraoperative opioid consumption, leading to fewer intraoperative hypotensive events.
The new study, justpublished in the British Journal of Anaesthesia (BJA),1followed 50 patients undergoing elective abdominal surgery in a two-center randomized controlled trial. The patients were randomly divided so that one group received NOL-guided analgesia dosing during the surgery and the control group received analgesics according to standard of care (based on hemodynami monitoring). The study showed that while there was no increase in overall dosing in the NOL-guided group, the patients in that group reported less pain in the first 90 minutes compared to the control arm.
In addition, stress hormone levels (ACTH and cortisol)were on average up to 50% lower in the NOL-guided group, which clinically aligns with the lower pain response levels in those patients during surgery.
“Clinicians using NOL monitoring to guide analgesia are able to identify more accurately when a patient’s pain response level rises and to tailoranalgesic medication more accurately. As we found that opioiddosing overall was not different between the groups, we can confidently relate the difference in outcomes to the timing of individualized dosing as guided by the NOL monitor,” Prof. Dahan concluded.